Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and antitumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)

被引：0
|
作者：
Olszanski, A. J. [1 ]
Luke, J. J. [2 ]
LoRusso, P. M. [3 ]
Falchook, G. S. [4 ]
Bedard, P. L. [5 ]
Sanborn, R. E. [6 ]
Patel, S. P. [7 ]
Orr, D. [8 ]
Gibbs, J. P. [9 ]
Li, C. [9 ]
Huang, Y-C. [9 ]
Gregory, R. [9 ]
Perera, S. [9 ]
Xu, R. [9 ]
Joshi, A. [9 ]
Lee, M. Y. [9 ]
Raizer, J. [9 ]
Gao, X. [10 ]
机构：
[1] Fox Chase Canc Ctr, Med Oncol, Philadelphia, PA USA
[2] Univ Pittsburgh, Canc Immunotherapeut Ctr, Med, Pittsburgh, PA USA
[3] Yale Canc Ctr, Med Oncol, New Haven, CT USA
[4] Sarah Cannon Res Inst SCRI HealthONE, Drug Dev Unit, Denver, CO USA
[5] Univ Hlth Network, Div Med Oncol & Hematol, Toronto, ON, Canada
[6] Earle A Chiles Res Inst, Providence Canc Inst, Oncol, Portland, OR USA
[7] Univ Calif San Diego, Oncol, Moores Canc Ctr, La Jolla, CA USA
[8] Mary Crowley Canc Res, Oncol, Dallas, TX USA
[9] Takeda Dev Ctr Amer Inc TDCA, Lexington, MA USA
[10] Massachusetts Gen Hosp, Med, Boston, MA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1029P
引用
收藏
页码：S625 / S626
页数：2
相关论文
共 50 条
  • [21] Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial
    Patnaik, Amita
    Weiss, Glen J.
    Rasco, Drew W.
    Blaydorn, Lisa
    Mirabella, Amy
    Beeram, Murali
    Guo, Wei
    Lu, Sharon
    Danaee, Hadi
    McEachern, Kristen
    Im, Ellie
    Sachdev, Jasgit C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (01) : 93 - 103
  • [22] Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalation/expansion results
    Voskoboynik, M.
    Mileshkin, L.
    Gan, H.
    Millward, M.
    Au-Yeung, G.
    Meniawy, T. M.
    Kichenadasse, G.
    Zhang, K.
    Zhang, M.
    Mu, S.
    Lickliter, J. D.
    ANNALS OF ONCOLOGY, 2019, 30
  • [23] IL believe: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon IL-2 ß/γ alone or in combination with pembrolizumab or standard-of-care chemotherapy in patients with locally advanced or metastatic solid tumors
    Starodub, Alexander
    Gabrail, Nashat Y.
    Zhang, Ying
    Castro, Davis Y. Torrejon
    Slavsky, Sibel
    Singel, Stina Mui
    Powderly, John D.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] transcendIT-101: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors.
    Davar, Diwakar
    Singel, Stina M.
    Nyamuswa, Gil
    Tuan-Anh Tran
    Wu, Yang
    Grewal, Jaspreet
    Aghmesheh, Morteza
    Spira, Alexander
    Ganju, Vinod
    Rand, Jamie
    Frentzas, Sophia
    Bajor, David
    Gabrail, Nashat
    CANCER RESEARCH, 2022, 82 (12)
  • [25] A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus weekly gemcitabine (Gem) in patients (pts) with advanced solid tumors: preliminary results
    Patnaik, A.
    Pipas, M.
    Rosen, L. S.
    Wood, L.
    Phipps, K.
    Mulay, M.
    Garay, C.
    Korc, M.
    Sarantopoulos, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] A phase 1b, open-label, dose escalation and expansion study of demcizumab plus pembrolizumab in patients with locally advanced or metastatic solid tumors
    Johnson, Melissa
    Rasco, Drew
    Schneider, Brian
    Shu, Catherine
    Jotte, Robert
    Parmer, Hema
    Stagg, Robert
    Lopez, Juanita
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [27] PHASE I DOSE ESCALATION AND PHARMACOKINETIC (PK) STUDY OF IV AFLIBERCEPT (VEGF TRAP) PLUS WEEKLY GEMCITABINE AND DAILY ERLOTINIB IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS: PRELIMINARY RESULTS
    Sarantopoulos, J.
    Rosen, L.
    Chap, L.
    Mita, A.
    Papadopoulos, K.
    Mita, M.
    Wood, L.
    Nichols, S.
    Tolcher, A.
    Trembly, J.
    Patnaik, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 57 - 57
  • [28] A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus FOLFOX4 in patients (pts) with advanced solid tumors: Preliminary results
    Limentani, S.
    Just, R.
    Purdham, A.
    Mulay, M.
    Bair, A.
    Tamby, J. F.
    Chap, L. I.
    Rosen, L. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] MULTICENTER, DOSE-ESCALATION STUDY OF THE INVESTIGATIONAL DRUG TAK-733, AN ORAL MEK INHIBITOR, IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS: PRELIMINARY PHASE 1 RESULTS
    Adjei, A. A.
    LoRusso, P. M.
    Ribas, A.
    Sosman, J. A.
    Dy, G. K.
    Chmielowski, B.
    Lipman, P.
    Zhou, X.
    Gangolli, E.
    Bozon, V.
    ANNALS OF ONCOLOGY, 2012, 23 : 158 - 158
  • [30] A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients (pts) with advanced solid tumors
    Papadopoulos, K. P.
    Markman, B.
    Tabernero, J.
    Patnaik, A.
    Heath, E. I.
    DeCillis, A.
    Laird, D.
    Aggarwal, S. K.
    Nguyen, L.
    LoRusso, P. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345